KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Assets Average (2019 - 2025)

Historic Assets Average for Castle Biosciences (CSTL) over the last 7 years, with Q3 2025 value amounting to $553.8 million.

  • Castle Biosciences' Assets Average rose 1054.4% to $553.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $553.8 million, marking a year-over-year increase of 1054.4%. This contributed to the annual value of $492.3 million for FY2024, which is 931.6% up from last year.
  • Per Castle Biosciences' latest filing, its Assets Average stood at $553.8 million for Q3 2025, which was up 1054.4% from $523.2 million recorded in Q2 2025.
  • Over the past 5 years, Castle Biosciences' Assets Average peaked at $553.8 million during Q3 2025, and registered a low of $426.1 million during Q2 2023.
  • In the last 5 years, Castle Biosciences' Assets Average had a median value of $452.6 million in 2022 and averaged $466.2 million.
  • Its Assets Average has fluctuated over the past 5 years, first skyrocketed by 26527.04% in 2021, then plummeted by 597.82% in 2023.
  • Quarter analysis of 5 years shows Castle Biosciences' Assets Average stood at $448.1 million in 2021, then increased by 0.99% to $452.6 million in 2022, then fell by 1.74% to $444.7 million in 2023, then grew by 17.59% to $522.9 million in 2024, then grew by 5.9% to $553.8 million in 2025.
  • Its Assets Average was $553.8 million in Q3 2025, compared to $523.2 million in Q2 2025 and $516.5 million in Q1 2025.